



SENSITIVE

PANEL REPORT

CALL	
Call:	HORIZON-JU-GH-EDCTP3-2025-04-two-stage
Topic:	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02
Type of action:	RIA
Service:	GH EDCTP3 JU
Call deadline:	03/09/2025 (stage 2)
Submission model:	Two-stage
Panel:	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage
Date of the panel meeting	16/10/2025
Evaluators:	<div> <div>[REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]</div> <div>[REDACTED]</div> </div>

TABLE OF CONTENTS

1. BACKGROUND AND SCOPE	2
2. PANEL REVIEW	2
2.1 Analysis of consensus results — Evaluation summary reports (ESR)	3
2.2 Panel ranked list — Priority order.....	3
2.3 Evaluation outcome	4
3. ADDITIONAL COMMENTS AND RECOMMENDATIONS.....	4
ANNEXES.....	5

1. BACKGROUND AND SCOPE

This report describes the results of the **panel review** done by the evaluation committee/panel for the evaluation of the following topic:

Topic: HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02

Call: HORIZON-JU-GH-EDCTP3-2025-04-two-stage

Published: 30.01.2025

Deadline: 20.03.2025 (stage 1); 03.09.2025 (stage 2)

Budget:

Total call budget: EUR 49.100.000,00

Budget for the topic: EUR 17.100.000,00.

This call covers the following topics/types of action:

Topic code	Topic name	Types of action
HORIZON-JU-GH-EDCTP3-2025-04 - CH-01-two-stage	Tackling diarrhoeal diseases in the context of climate and health	Research and Innovation Actions
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	Transformative Innovations in global health	Research and Innovation Actions

The evaluation was made in accordance with the applicable legal framework and guidance.

2. PANEL REVIEW

The evaluation committee/panel examined and compared the consensus reports (CRs) of the proposals and checked consistency of the comments and the scores against the award criteria set out in the call conditions (**evaluation**).

The committee also examined the answers to the **additional questions** asked (if any; exceptional funding).

The committee/panel made — for each proposal — an **evaluation summary report (ESR)** (see Annex 3).

On the basis of the scores in the evaluation summary reports, the committee/panel then made a **panel ranked list** (see Annex 1) — also recommending (if necessary) a **priority order** for proposals with the same score (in accordance with the procedure set out in the call conditions).

2.1 Analysis of consensus results — Evaluation summary reports (ESR)

After analysis of the consensus results, the evaluation committee/panel considers the evaluation consistent. The scores and the comments on the award criteria in the **consensus reports** are confirmed.

2.2 Panel ranked list — Priority order

On the basis of the scores retained in the evaluation summary reports (ESRs), the evaluation committee/panel made a **panel ranked list** for above-threshold proposals.

This ranking is based on the overall score (defined as the *unweighted* sum of the scores of the individual award criteria).

For above-threshold proposals with an equal score, the evaluation committee/panel recommends the following **priority order** (in accordance with the method set out in the call conditions) (if applicable):

Proposals with an overall score of : 14			
Priority	Project number	Project acronym	Reasons
a	101248850-2	PATHFINDER	Ex-aequo criterion 2: higher score for excellence
b	101248873-2	ACT4KIDS-TB	

Proposals with an overall score of : 13.5			
Priority	Project number	Project acronym	Reasons
a	101248978-2	ACT-Africa	Ex-aequo criterion 2: higher score for excellence
b	101249082-2	M-Pact	Ex-aequo criterion 2: higher score for impact
c	101248923-2	ParasiteAID	

Proposals with an overall score of : 13			
Priority	Project number	Project acronym	Reasons
a	101248841-2	MRI of the Tyger	Ex-aequo criterion 2: higher score for impact
b	101248953-2	FRONTLINE	

Proposals with an overall score of : 12.5			
Priority	Project number	Project acronym	Reasons
a	101249036-2	InfectoTest	Ex-aequo criterion 1: portfolio diversification
b	101248865-2	TB-DISCOVER	

2.3 Evaluation outcome

Table A: Number of evaluated proposals and evaluation outcome.

Topic code	Number of evaluated proposals	Number of below-threshold proposals		Number of above-threshold proposals	
HORIZON-JU-GH-EDCTP3-2025-04 -CH-01-two-stage	10	6	60%	4	40%
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	26	9	34,6%	17	65,4%
Total	36	15	41,6%	21	58,4%

For the panel ranked list, along with a final score and the evaluation committee/panel recommendations for priority order, see Annex 1.

For the list of below-threshold proposals, see Annex 2.

For the evaluation summary reports (ESRs), see Annex 3.

3. ADDITIONAL COMMENTS AND RECOMMENDATIONS

NA

Panel Chair
Milan POPOVIC

Call Coordinator
Erika GASPARI

ANNEXES

LIST OF ANNEXES

Annex 1	Panel ranked list
Annex 2	List of below-threshold proposals
Annex 3	Evaluation summary reports (ESRs)
Annex 4	Consolidated information on the additional questions
	Annex 4a List of proposals involving exceptional funding
	Annex 4b List of proposals involving hESC (NA)
Annex 5	Panel hearing minutes (NA)
Annex 7	Report on SEP actions on behalf of experts (NA)
Annex 8	Report on conflict of interests

PANEL RANKED LIST

Rank	Proposal Number	Proposal Acronym	Total Score	Evaluation Status	Number of Participants	SME Participants	Proposal Budget	Proposal Duration	Requested Grant	SME Requested Grant	Expert Recommended Grant	Expert Cumulative Budget
1	101249120-2	TEST4TPT	15	Above Threshold	8	2	2,248,981.25 €	36	2,248,981.25 €	532,957.50 €	2,248,981.25 €	2,248,981.25 €
2	101248882-2	ASAQ-PAC	15	Above Threshold	5	2	2,099,745.75 €	36	2,099,745.75 €	1,117,288.25 €	2,099,745.75 €	4,348,727.00 €
3	101248942-2	R2D2-xDRTB	14.5	Above Threshold	4	0	2,099,625.50 €	36	2,099,625.50 €	0.00 €	2,099,625.50 €	6,448,352.50 €
4	101249004-2	RECENT-TB	14.5	Above Threshold	5	0	2,394,773.75 €	48	2,394,773.75 €	0.00 €	2,394,773.75 €	8,843,126.25 €
5	101248855-2	AddiCAD	14.5	Above Threshold	6	3	2,564,405.25 €	36	2,176,905.25 €	706,248.75 €	2,176,905.25 €	11,020,031.50 €
6	101249059-2	SWAB -IMPACT	14.5	Above Threshold	3	0	2,369,338.75 €	36	2,352,258.75 €	0.00 €	2,352,258.75 €	13,372,290.25 €
7	101248845-2	PRECISE-TBM	14.5	Above Threshold	6	2	2,158,288.75 €	48	2,158,288.75 €	877,875.00 €	2,158,288.75 €	15,530,579.00 €
8	101248850-2	PATHFINDER	14	Above Threshold	6	1	2,753,913.75 €	42	2,753,913.75 €	759,966.25 €	2,753,913.75 €	18,284,492.75 €
9	101248873-2	ACT4KIDS-TB	14	Above Threshold	6	0	2,059,163.75 €	48	2,059,163.75 €	0.00 €	2,059,163.75 €	20,343,656.50 €
10	101248978-2	ACT-Africa	13.5	Above Threshold	8	0	2,000,000.00 €	50	2,000,000.00 €	0.00 €	2,000,000.00 €	22,343,656.50 €
11	101249082-2	M-Pact	13.5	Above Threshold	6	1	2,287,992.50 €	36	2,287,992.50 €	93,750.00 €	2,287,992.50 €	24,631,649.00 €
12	101248923-2	ParasiteAID	13.5	Above Threshold	13	3	2,089,091.25 €	48	2,089,091.25 €	877,653.75 €	2,089,091.25 €	26,720,740.25 €
13	101248841-2	MRI of the Tyger	13	Above Threshold	6	1	2,499,336.25 €	36	2,499,336.25 €	796,250.00 €	2,499,336.25 €	29,220,076.50 €
14	101248953-2	FRONTLINE	13	Above Threshold	8	1	2,299,999.25 €	36	2,299,999.25 €	116,461.25 €	2,299,999.25 €	31,520,075.75 €
15	101249036-2	InfectoTest	12.5	Above Threshold	6	2	2,329,905.50 €	36	2,329,905.50 €	972,412.50 €	2,329,905.50 €	33,849,981.25 €
16	101248865-2	TB-DISCOVER	12.5	Above Threshold	3	0	2,060,923.75 €	36	2,060,923.00 €	0.00 €	2,060,923.00 €	35,910,904.25 €
17	101248837-2	SERMAVAL	12	Above Threshold	5	0	2,297,500.00 €	30	2,297,500.00 €	0.00 €	2,297,500.00 €	38,208,404.25 €
18	101249056-2	TB MetNac	12	Below Threshold	5	0	2,311,060.00 €	36	2,300,435.00 €	0.00 €	2,300,435.00 €	40,508,839.25 €
19	101249123-2	R-RDT4TB	11	Below Threshold	13	3	2,360,865.00 €	48	2,360,865.00 €	548,345.00 €	2,360,865.00 €	42,869,704.25 €
20	101248985-2	eHEALNTD	10.5	Below Threshold	9	2	2,705,060.00 €	48	2,705,060.00 €	729,375.00 €	2,705,060.00 €	45,574,764.25 €
21	101248939-2	C2K-ACCESS	10.5	Below Threshold	6	0	2,740,830.00 €	48	2,740,830.00 €	0.00 €	2,740,830.00 €	48,315,594.25 €
22	101249009-2	INASMAL	10	Below Threshold	6	1	2,883,533.75 €	48	2,814,934.75 €	780,500.00 €	2,814,934.75 €	51,130,529.00 €
23	101248987-2	AzithroTAB	10	Below Threshold	8	1	2,414,426.50 €	42	2,414,426.50 €	248,281.25 €	2,414,426.50 €	53,544,955.50 €
24	101249071-2	TACTIC	9.5	Below Threshold	3	0	2,476,826.25 €	48	2,300,000.00 €	0.00 €	2,300,000.00 €	55,844,955.50 €
25	101248848-2	BCG-SSA	8.5	Below Threshold	3	0	2,100,000.00 €	60	2,100,000.00 €	0.00 €	2,100,000.00 €	57,944,955.50 €
26	101249113-2	LIFE3	6	Below Threshold	10	0	7,209,620.00 €	60	7,209,620.00 €	0.00 €	7,209,620.00 €	65,154,575.50 €

LIST OF BELOW-THRESHOLD PROPOSALS

Proposal Number	Proposal Acronym	Proposal Title	Reason	Requested Grant	ESR Score
101249123-2	R-RDT4TB	REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Proposal failed to pass the threshold of multiple criteria	2,360,865 €	11
101249009-2	INASMAL	MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND SEVERE MALARIA	Proposal failed to pass the threshold of multiple criteria	2,814,935 €	10
101249113-2	LIFE3	Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Proposal failed to pass the threshold of multiple criteria	7,209,620 €	6
101248985-2	eHEALNTD	Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Proposal failed to pass the threshold of criterion 3	2,705,060 €	10.5
101248987-2	AzithroTAB	Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Proposal failed to pass the threshold of multiple criteria	2,414,427 €	10
101248939-2	C2K-ACCESS	Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Proposal failed to pass the threshold of criterion 3	2,740,830 €	10.5
101249071-2	TACTIC	TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	Proposal failed to pass the threshold of multiple criteria	2,300,000 €	9.5
101249056-2	TB MetNac	PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Proposal failed to pass the threshold of criterion 1	2,300,435 €	12
101248848-2	BCG-SSA	Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-SeniorS-Africa)	Proposal failed to pass the threshold of multiple criteria	2,100,000 €	8.5

LIST OF EVALUATION SUMMARY REPORTS (ESRs)

The evaluation summary reports for the following proposals are attached:

Proposal Number	Proposal Acronym
101249120-2	TEST4TPT
101248882-2	ASAQ-PAC
101248942-2	R2D2-xDRTB
101249004-2	RECENT-TB
101248855-2	AddiCAD
101249059-2	SWAB -IMPACT
101248845-2	PRECISE-TBM
101248850-2	PATHFINDER
101248873-2	ACT4KIDS-TB
101248978-2	ACT-Africa
101249082-2	M-Pact
101248923-2	ParasiteAID
101248841-2	MRI of the Tyger
101248953-2	FRONTLINE
101249036-2	InfectoTest
101248865-2	TB-DISCOVER
101248837-2	SERMAVAL
101249056-2	TB MetNac
101249123-2	R-RDT4TB
101248985-2	eHEALNTD
101248939-2	C2K-ACCESS
101249009-2	INASMAL
101248987-2	AzithroTAB
101249071-2	TACTIC
101248848-2	BCG-SSA
101249113-2	LIFE3

ADDITIONAL QUESTIONS

Proposal Number	Proposal Acronym	Participant(s) that should exceptionally be funded	Participant(s) that should NOT be funded
101248923-2	ParasiteAID	Cairo University, due to access to geographical environments and access to data	
101248942-2	R2D2-xDRTB	Schweizerisches Tropen und Public Health Institut from Switzerland is requesting 372592.50 euros. Given its exceptional expertise in tuberculosis and implementation science and important contributions to several work packages (in particular the adaptive platform trial), the evaluators consider its inclusion in the project to be essential for successful project implementation. Schweizerisches Tropen und Public Health Institut should therefore receive exceptional funding of 372592.50 euros.	
101249059-2	SWAB -IMPACT	The Centre for Infectious Diseases Research in Zambia, an international organisation not automatically eligible for EU funding, is requesting 764163.75 euros. Given its particular geographic environment and outstanding competence, the evaluators consider its inclusion in the project to be essential for successful project implementation. The Centre for Infectious Diseases Research in Zambia should therefore receive exceptional funding of 764163.75 euros.	

